Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

Eli Lilly reported Q4 2025 revenue of $19.292 billion, up 43% year-over-year, with reported EPS of $7.39 (+51%) and non-GAAP EPS of $7.54 (+42%), driven by strong volume growth in Mounjaro ($7.409B, +110%) and Zepbound ($4.261B, +123%). Full-year 2025 revenue was $65.179 billion (+45%) with net income of $20.64 billion (+95%); management issued 2026 guidance of $80–$83 billion in revenue and non-GAAP EPS of $33.50–$35.00, while highlighting FDA approvals, multiple positive Phase 3 readouts and an agreement with the U.S. government to expand access to obesity medicines.

Analysis

Market structure: Lilly (LLY) is a clear near-term winner — Q4 revenue +43% and Mounjaro/Zepbound double-digit growth (Mounjaro +110% q/q YoY) indicate demand shock in GLP-1/incretin markets that reallocates share from incumbents and smaller players. Payers and governments are the implicit losers (cost burden); Lilly's voluntary US access agreement reduces pure pricing upside and increases volume sensitivity. Manufacturing/CMO capacity becomes a strategic choke point: durable pricing power depends on scaling peptide supply over next 6–18 months.

Risk assessment: Material tail risks include (1) US price concessions or mandatory reimbursement caps within 12 months, (2) FDA/adverse-signal actions on tirzepatide/oral competitors, and (3) manufacturing bottlenecks slowing growth. Immediate (days) volatility will track guidance interpretation; short-term (weeks–months) risk centers on regulatory decisions (orforglipron submissions, Kwikpen approval impacts); long-term (quarters–years) depends on pipeline readouts (retatrutide) and sustained market share shifts.

Trade implications: Prefer concentrated LLY exposure vs peers — asymmetric upside tied to successful oral GLP-1 adoption and retatrutide durability. Cross-asset: expect tighter LLY credit spreads and marginally firmer AUD/JPY for pharma exporters; elevated equity-option IV on GLP-1 makers for 3–9 months. Rotate into large-cap endocrine/peptide manufacturers and contract manufacturers; reduce exposure to mid/small-cap diabetes franchises lacking scale.

Contrarian angles: Consensus underprices downside from access deals and supply constraints — upside may be capped even as volumes surge. Conversely, market may underappreciate upside from switch-to-oral dynamics (orforglipron) that could expand TAM by >30% over 3 years; trade discipline around 10–15% price moves and concrete regulatory readouts will reveal mispricings.

Key Decisions for Investors

• Establish a 2–3% long position in LLY common stock (time horizon 6–12 months); target asymmetric return of +15–25% if guidance execution and orforglipron/retatrutide readouts are positive; implement a hard stop-loss at 10% below entry and trim on a 25% rally.
• Buy a 9-month LLY call spread (approx. Feb 2027 expiry) sized at 1–1.5% notional: buy 10% OTM call / sell 30% OTM call to cap premium while capturing upside from continued Mounjaro/Zepbound momentum and pipeline catalysts; close on negative safety/regulatory news or on >30% move in IV.
• Execute a pair trade: long LLY 3% vs short NVO (Novo Nordisk) 1.5–2% notional (hold 6–12 months) to capture expected share gains from tirzepatide franchise; unwind if relative performance reverses by 10% or if payer price caps are announced affecting both equally.
• If VTYX remains publicly tradeable below announced consideration, size 0.5–1% arbitrage long (tender arbitrage) with a 15% stop; if acquisition completed, convert proceeds to LLY exposure. Monitor FDA decisions (orforglipron +90 days, Kwikpen impacts) as binary catalysts to add to LLY position up to 4% if outcomes are positive.